Multiple myeloma historical perspective: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) |
||
| Line 12: | Line 12: | ||
*In '''1961''', the use of thalidomide was prohibited since it was found to be associated with birth defects.<ref name="pmid27604794">{{cite journal| author=Hong J, Lee JH| title=Recent advances in multiple myeloma: a Korean perspective. | journal=Korean J Intern Med | year= 2016 | volume= 31 | issue= 5 | pages= 820-34 | pmid=27604794 | doi=10.3904/kjim.2015.408 | pmc=5016289 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27604794 }} </ref> | *In '''1961''', the use of thalidomide was prohibited since it was found to be associated with birth defects.<ref name="pmid27604794">{{cite journal| author=Hong J, Lee JH| title=Recent advances in multiple myeloma: a Korean perspective. | journal=Korean J Intern Med | year= 2016 | volume= 31 | issue= 5 | pages= 820-34 | pmid=27604794 | doi=10.3904/kjim.2015.408 | pmc=5016289 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27604794 }} </ref> | ||
*In the 1990s, it was shown that high-dose therapy with autologous stem cell rescue led to improved patient outcomes.<ref name="pmid27604794">{{cite journal| author=Hong J, Lee JH| title=Recent advances in multiple myeloma: a Korean perspective. | journal=Korean J Intern Med | year= 2016 | volume= 31 | issue= 5 | pages= 820-34 | pmid=27604794 | doi=10.3904/kjim.2015.408 | pmc=5016289 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27604794 }} </ref> | *In the 1990s, it was shown that high-dose therapy with autologous stem cell rescue led to improved patient outcomes.<ref name="pmid27604794">{{cite journal| author=Hong J, Lee JH| title=Recent advances in multiple myeloma: a Korean perspective. | journal=Korean J Intern Med | year= 2016 | volume= 31 | issue= 5 | pages= 820-34 | pmid=27604794 | doi=10.3904/kjim.2015.408 | pmc=5016289 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27604794 }} </ref> | ||
*In '''1999''', Singhal and colleagues showed | *In '''1999''', Singhal and colleagues showed that thalidomide had a 32% response rate in a phase II clinical trial of relapsed/refractory multiple myeloma. | ||
*In '''2003''', the proteasome inhibitor bortezomib was approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma. | |||
*In '''2014''', the International Myeloma Working Group (IMWG) revised the diagnostic criteria for active multiple myeloma to include bone marrow plasma cell burden > 60%, serum free light chain ratio > 100, and greater than 1 bony lesion on MRI. | |||
== References == | == References == | ||
Revision as of 23:01, 14 July 2018
|
Multiple myeloma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple myeloma historical perspective On the Web |
|
American Roentgen Ray Society Images of Multiple myeloma historical perspective |
|
Risk calculators and risk factors for Multiple myeloma historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
Multiple myeloma was first discovered by Dr. Samuel Solly, a surgeon working in St.Thomas hospital in London in 1844.[1]The Bence Jones protein was first discovered by Dr. Henry Bence Jones and found to be associated with multiple myeloma in 1850; And the term “Bence Jones protein” was first used by Fleischer in 1880. PMID:29194778
Historical Perspective
- In 1844, Dr. Samuel Solly first discovered multiple myeloma. He was a a surgeon working in St.Thomas hospital at London.[2]
- In 1850, Dr. Henry Bence Jones first described the Bence Jones protein and found it to be associated with multiple myeloma.[3]
- In the 1960s, the chemotherapy agent melphalan was shown to improve overall survival in multiple myeloma.[4]
- In 1961, the use of thalidomide was prohibited since it was found to be associated with birth defects.[4]
- In the 1990s, it was shown that high-dose therapy with autologous stem cell rescue led to improved patient outcomes.[4]
- In 1999, Singhal and colleagues showed that thalidomide had a 32% response rate in a phase II clinical trial of relapsed/refractory multiple myeloma.
- In 2003, the proteasome inhibitor bortezomib was approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma.
- In 2014, the International Myeloma Working Group (IMWG) revised the diagnostic criteria for active multiple myeloma to include bone marrow plasma cell burden > 60%, serum free light chain ratio > 100, and greater than 1 bony lesion on MRI.
References
- ↑ Moehler T, Goldschmidt H. Multiple Myeloma. Springer Science & Business Media; 2011. https://books.google.com/books?isbn=3540857729
- ↑ Moehler T, Goldschmidt H. Multiple Myeloma. Springer Science & Business Media; 2011. https://books.google.com/books?isbn=3540857729
- ↑ Kyle RA, Steensma DP (2011). "History of multiple myeloma". Recent Results Cancer Res. 183: 3–23. doi:10.1007/978-3-540-85772-3_1. PMID 21509678.
- ↑ 4.0 4.1 4.2 Hong J, Lee JH (2016). "Recent advances in multiple myeloma: a Korean perspective". Korean J Intern Med. 31 (5): 820–34. doi:10.3904/kjim.2015.408. PMC 5016289. PMID 27604794.